Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY™ ELLIPTA™) When Compared With Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients Within a Usual Care Setting

Next Previous
Trial Profile

The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY™ ELLIPTA™) When Compared With Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients Within a Usual Care Setting

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 09 Nov 2022 Results assessing to use linked routine Netherlands healthcare data to assess the validity and practicality of future pragmatic trials using this external database as a method to ascertain healthcare resource utilisation (HCRU) outcomes presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
  • 09 Nov 2022 Results assessing the validity and practicality of future pragmatic trials to ascertain healthcare resource utilisation (HCRU) outcomes by deriving data from INTREPID ,presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
  • 20 May 2020 Primary endpoint, Number of responders based on CAT at Week 24, has been met as per results presented at the 116th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top